nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—CYP1A1—Thalidomide—leprosy	0.121	0.169	CbGbCtD
Gefitinib—CYP3A5—Thalidomide—leprosy	0.0726	0.102	CbGbCtD
Gefitinib—CYP3A5—Rifampicin—leprosy	0.0703	0.0984	CbGbCtD
Gefitinib—CYP2C19—Thalidomide—leprosy	0.0586	0.082	CbGbCtD
Gefitinib—CYP3A5—Dapsone—leprosy	0.058	0.0812	CbGbCtD
Gefitinib—CYP2C19—Rifampicin—leprosy	0.0567	0.0794	CbGbCtD
Gefitinib—CYP2C9—Thalidomide—leprosy	0.0487	0.0681	CbGbCtD
Gefitinib—CYP2C9—Rifampicin—leprosy	0.0471	0.066	CbGbCtD
Gefitinib—CYP2C19—Dapsone—leprosy	0.0468	0.0655	CbGbCtD
Gefitinib—ABCB1—Rifampicin—leprosy	0.0458	0.064	CbGbCtD
Gefitinib—CYP2C9—Dapsone—leprosy	0.0389	0.0545	CbGbCtD
Gefitinib—CYP3A4—Rifampicin—leprosy	0.0274	0.0384	CbGbCtD
Gefitinib—CYP3A4—Dapsone—leprosy	0.0226	0.0317	CbGbCtD
Gefitinib—Vandetanib—RIPK2—leprosy	0.00692	1	CrCbGaD
Gefitinib—ERBB3—peripheral nervous system—leprosy	0.00621	0.0973	CbGeAlD
Gefitinib—Gastrointestinal perforation—Thalidomide—leprosy	0.00588	0.0587	CcSEcCtD
Gefitinib—Hypoproteinaemia—Thalidomide—leprosy	0.00522	0.0521	CcSEcCtD
Gefitinib—SBK1—eye—leprosy	0.00379	0.0595	CbGeAlD
Gefitinib—Proteinuria—Dapsone—leprosy	0.00341	0.034	CcSEcCtD
Gefitinib—Protein urine present—Dapsone—leprosy	0.00337	0.0336	CcSEcCtD
Gefitinib—Vesiculobullous rash—Thalidomide—leprosy	0.00274	0.0273	CcSEcCtD
Gefitinib—Gastric ulcer—Thalidomide—leprosy	0.00264	0.0263	CcSEcCtD
Gefitinib—Febrile neutropenia—Thalidomide—leprosy	0.00255	0.0255	CcSEcCtD
Gefitinib—SBK1—tendon—leprosy	0.00251	0.0394	CbGeAlD
Gefitinib—Hypomagnesaemia—Thalidomide—leprosy	0.00242	0.0241	CcSEcCtD
Gefitinib—Nail disorder—Thalidomide—leprosy	0.00237	0.0236	CcSEcCtD
Gefitinib—Seborrhoeic dermatitis—Thalidomide—leprosy	0.00225	0.0225	CcSEcCtD
Gefitinib—CHEK2—tendon—leprosy	0.00219	0.0343	CbGeAlD
Gefitinib—Interstitial lung disease—Thalidomide—leprosy	0.00217	0.0216	CcSEcCtD
Gefitinib—SBK1—testis—leprosy	0.00208	0.0326	CbGeAlD
Gefitinib—IRAK1—activated TAK1 mediates p38 MAPK activation—NOD2—leprosy	0.00208	0.0181	CbGpPWpGaD
Gefitinib—HIPK4—testis—leprosy	0.00206	0.0322	CbGeAlD
Gefitinib—Pleural effusion—Thalidomide—leprosy	0.002	0.02	CcSEcCtD
Gefitinib—Amblyopia—Thalidomide—leprosy	0.00199	0.0198	CcSEcCtD
Gefitinib—Rash pustular—Thalidomide—leprosy	0.00192	0.0192	CcSEcCtD
Gefitinib—MKNK2—eye—leprosy	0.00192	0.0301	CbGeAlD
Gefitinib—MKNK1—eye—leprosy	0.0019	0.0298	CbGeAlD
Gefitinib—Pancreatitis—Dapsone—leprosy	0.00184	0.0184	CcSEcCtD
Gefitinib—Acne—Thalidomide—leprosy	0.00182	0.0182	CcSEcCtD
Gefitinib—CSNK1E—skin of body—leprosy	0.00182	0.0286	CbGeAlD
Gefitinib—CHEK2—testis—leprosy	0.00181	0.0284	CbGeAlD
Gefitinib—CYP1A1—skin epidermis—leprosy	0.00181	0.0284	CbGeAlD
Gefitinib—ERBB3—skin of body—leprosy	0.00176	0.0276	CbGeAlD
Gefitinib—Proteinuria—Thalidomide—leprosy	0.00175	0.0174	CcSEcCtD
Gefitinib—IRAK4—Interleukin-1 signaling—RIPK2—leprosy	0.00174	0.0152	CbGpPWpGaD
Gefitinib—IRAK1—Endogenous TLR signaling—TLR2—leprosy	0.00174	0.0152	CbGpPWpGaD
Gefitinib—IRAK1—IL1 and megakaryotyces in obesity—TLR2—leprosy	0.00174	0.0152	CbGpPWpGaD
Gefitinib—Protein urine present—Thalidomide—leprosy	0.00172	0.0172	CcSEcCtD
Gefitinib—Drug interaction—Thalidomide—leprosy	0.00165	0.0165	CcSEcCtD
Gefitinib—IRAK1—TAK1 activates NFkB by phosphorylation and activation of IKKs complex—RIPK2—leprosy	0.00163	0.0142	CbGpPWpGaD
Gefitinib—EPHA6—testis—leprosy	0.00163	0.0255	CbGeAlD
Gefitinib—IRAK4—Toll-like Receptor Signaling Pathway—TLR1—leprosy	0.00162	0.0141	CbGpPWpGaD
Gefitinib—EPHA6—nervous system—leprosy	0.0016	0.025	CbGeAlD
Gefitinib—IRAK4—Interleukin-1 signaling—NOD2—leprosy	0.00158	0.0138	CbGpPWpGaD
Gefitinib—IRAK1—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—CYLD—leprosy	0.0015	0.0131	CbGpPWpGaD
Gefitinib—IRAK1—TAK1 activates NFkB by phosphorylation and activation of IKKs complex—NOD2—leprosy	0.00148	0.0129	CbGpPWpGaD
Gefitinib—MAP3K19—testis—leprosy	0.00148	0.0232	CbGeAlD
Gefitinib—MAP3K19—nervous system—leprosy	0.00145	0.0227	CbGeAlD
Gefitinib—Dry eye—Thalidomide—leprosy	0.00142	0.0141	CcSEcCtD
Gefitinib—IRAK1—NOD1/2 Signaling Pathway—RIPK2—leprosy	0.00142	0.0124	CbGpPWpGaD
Gefitinib—CSNK1E—tendon—leprosy	0.00139	0.0217	CbGeAlD
Gefitinib—IRAK4—tendon—leprosy	0.00137	0.0214	CbGeAlD
Gefitinib—Thrombophlebitis—Thalidomide—leprosy	0.00129	0.0128	CcSEcCtD
Gefitinib—IRAK1—NOD1/2 Signaling Pathway—NOD2—leprosy	0.00128	0.0112	CbGpPWpGaD
Gefitinib—MKNK2—tendon—leprosy	0.00127	0.02	CbGeAlD
Gefitinib—IRAK1—tendon—leprosy	0.00127	0.02	CbGeAlD
Gefitinib—IRAK4—Regulation of toll-like receptor signaling pathway—TLR1—leprosy	0.00126	0.011	CbGpPWpGaD
Gefitinib—Eye pain—Thalidomide—leprosy	0.00123	0.0123	CcSEcCtD
Gefitinib—EGFR—testis—leprosy	0.00119	0.0187	CbGeAlD
Gefitinib—Dermatitis exfoliative—Thalidomide—leprosy	0.00118	0.0118	CcSEcCtD
Gefitinib—Atrial fibrillation—Thalidomide—leprosy	0.00118	0.0117	CcSEcCtD
Gefitinib—Dermatitis bullous—Thalidomide—leprosy	0.00117	0.0116	CcSEcCtD
Gefitinib—IRAK1—Interleukin-1 signaling—RIPK2—leprosy	0.00116	0.0101	CbGpPWpGaD
Gefitinib—CSNK1E—testis—leprosy	0.00115	0.018	CbGeAlD
Gefitinib—Cough—Dapsone—leprosy	0.00114	0.0114	CcSEcCtD
Gefitinib—IRAK4—testis—leprosy	0.00113	0.0177	CbGeAlD
Gefitinib—CSNK1E—nervous system—leprosy	0.00113	0.0177	CbGeAlD
Gefitinib—IRAK4—nervous system—leprosy	0.00111	0.0174	CbGeAlD
Gefitinib—ERBB3—testis—leprosy	0.00111	0.0174	CbGeAlD
Gefitinib—ERBB3—Apoptosis-related network due to altered Notch3 in ovarian cancer—RIPK2—leprosy	0.00111	0.00967	CbGpPWpGaD
Gefitinib—ERBB3—nervous system—leprosy	0.00109	0.0171	CbGeAlD
Gefitinib—IRAK1—Toll-like Receptor Signaling Pathway—TLR1—leprosy	0.00107	0.00936	CbGpPWpGaD
Gefitinib—MKNK2—testis—leprosy	0.00105	0.0165	CbGeAlD
Gefitinib—IRAK1—testis—leprosy	0.00105	0.0165	CbGeAlD
Gefitinib—IRAK1—Interleukin-1 signaling—NOD2—leprosy	0.00105	0.00914	CbGpPWpGaD
Gefitinib—MKNK1—testis—leprosy	0.00104	0.0163	CbGeAlD
Gefitinib—Dehydration—Thalidomide—leprosy	0.00104	0.0103	CcSEcCtD
Gefitinib—STK10—tendon—leprosy	0.00104	0.0162	CbGeAlD
Gefitinib—MKNK2—nervous system—leprosy	0.00103	0.0162	CbGeAlD
Gefitinib—MKNK1—nervous system—leprosy	0.00102	0.016	CbGeAlD
Gefitinib—Dry skin—Thalidomide—leprosy	0.00102	0.0102	CcSEcCtD
Gefitinib—Hypokalaemia—Thalidomide—leprosy	0.00101	0.0101	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Thalidomide—leprosy	0.001	0.01	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Thalidomide—leprosy	0.001	0.01	CcSEcCtD
Gefitinib—IRAK4—Regulation of toll-like receptor signaling pathway—CYLD—leprosy	0.000997	0.0087	CbGpPWpGaD
Gefitinib—Alanine aminotransferase increased—Thalidomide—leprosy	0.000983	0.0098	CcSEcCtD
Gefitinib—IRAK1—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—RIPK2—leprosy	0.000967	0.00844	CbGpPWpGaD
Gefitinib—IRAK4—MyD88 cascade initiated on plasma membrane—RIPK2—leprosy	0.000952	0.00831	CbGpPWpGaD
Gefitinib—Pancreatitis—Thalidomide—leprosy	0.000944	0.00942	CcSEcCtD
Gefitinib—IRAK4—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—RIPK2—leprosy	0.000944	0.00824	CbGpPWpGaD
Gefitinib—IRAK4—MyD88 dependent cascade initiated on endosome—RIPK2—leprosy	0.000926	0.00809	CbGpPWpGaD
Gefitinib—MAP2K5—tendon—leprosy	0.000925	0.0145	CbGeAlD
Gefitinib—IRAK4—Toll Like Receptor 9 (TLR9) Cascade—RIPK2—leprosy	0.000894	0.0078	CbGpPWpGaD
Gefitinib—IRAK1—MAP kinase activation in TLR cascade—RIPK2—leprosy	0.000883	0.00771	CbGpPWpGaD
Gefitinib—IRAK4—MyD88:Mal cascade initiated on plasma membrane—RIPK2—leprosy	0.000879	0.00767	CbGpPWpGaD
Gefitinib—IRAK4—MyD88:Mal cascade initiated on plasma membrane—TLR2—leprosy	0.000879	0.00767	CbGpPWpGaD
Gefitinib—IRAK1—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—NOD2—leprosy	0.000876	0.00765	CbGpPWpGaD
Gefitinib—Gastrointestinal pain—Dapsone—leprosy	0.000875	0.00873	CcSEcCtD
Gefitinib—Weight decreased—Thalidomide—leprosy	0.000871	0.00869	CcSEcCtD
Gefitinib—Pneumonia—Thalidomide—leprosy	0.000864	0.00861	CcSEcCtD
Gefitinib—IRAK4—MyD88 cascade initiated on plasma membrane—NOD2—leprosy	0.000864	0.00754	CbGpPWpGaD
Gefitinib—Infestation NOS—Thalidomide—leprosy	0.000859	0.00856	CcSEcCtD
Gefitinib—Infestation—Thalidomide—leprosy	0.000859	0.00856	CcSEcCtD
Gefitinib—STK10—testis—leprosy	0.000857	0.0134	CbGeAlD
Gefitinib—IRAK4—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NOD2—leprosy	0.000855	0.00747	CbGpPWpGaD
Gefitinib—Stevens-Johnson syndrome—Thalidomide—leprosy	0.000851	0.00849	CcSEcCtD
Gefitinib—Body temperature increased—Dapsone—leprosy	0.000846	0.00844	CcSEcCtD
Gefitinib—Abdominal pain—Dapsone—leprosy	0.000846	0.00844	CcSEcCtD
Gefitinib—STK10—nervous system—leprosy	0.000841	0.0132	CbGeAlD
Gefitinib—IRAK4—MyD88 dependent cascade initiated on endosome—NOD2—leprosy	0.00084	0.00733	CbGpPWpGaD
Gefitinib—IRAK1—Regulation of toll-like receptor signaling pathway—TLR1—leprosy	0.000837	0.00731	CbGpPWpGaD
Gefitinib—Stomatitis—Thalidomide—leprosy	0.000837	0.00835	CcSEcCtD
Gefitinib—Conjunctivitis—Thalidomide—leprosy	0.000835	0.00833	CcSEcCtD
Gefitinib—IRAK4—Toll-like Receptor Signaling Pathway—TLR2—leprosy	0.000823	0.00719	CbGpPWpGaD
Gefitinib—Haematuria—Thalidomide—leprosy	0.000819	0.00817	CcSEcCtD
Gefitinib—IRAK4—Toll Like Receptor 9 (TLR9) Cascade—NOD2—leprosy	0.000811	0.00707	CbGpPWpGaD
Gefitinib—Epistaxis—Thalidomide—leprosy	0.00081	0.00808	CcSEcCtD
Gefitinib—IRAK1—MAP kinase activation in TLR cascade—NOD2—leprosy	0.0008	0.00699	CbGpPWpGaD
Gefitinib—IRAK4—MyD88:Mal cascade initiated on plasma membrane—NOD2—leprosy	0.000797	0.00695	CbGpPWpGaD
Gefitinib—IRAK4—Signaling by Interleukins—RIPK2—leprosy	0.000786	0.00686	CbGpPWpGaD
Gefitinib—IRAK1—IL1 and megakaryotyces in obesity—IFNG—leprosy	0.000784	0.00684	CbGpPWpGaD
Gefitinib—Hepatitis—Thalidomide—leprosy	0.000771	0.00769	CcSEcCtD
Gefitinib—MAP2K5—testis—leprosy	0.000766	0.012	CbGeAlD
Gefitinib—Urinary tract disorder—Thalidomide—leprosy	0.000761	0.00759	CcSEcCtD
Gefitinib—Oedema peripheral—Thalidomide—leprosy	0.000759	0.00757	CcSEcCtD
Gefitinib—IRAK4—Activated TLR4 signalling—RIPK2—leprosy	0.000758	0.00662	CbGpPWpGaD
Gefitinib—IRAK4—Activated TLR4 signalling—TLR2—leprosy	0.000758	0.00662	CbGpPWpGaD
Gefitinib—Urethral disorder—Thalidomide—leprosy	0.000756	0.00754	CcSEcCtD
Gefitinib—MAP2K5—nervous system—leprosy	0.000751	0.0118	CbGeAlD
Gefitinib—IRAK1—p75(NTR)-mediated signaling—RIPK2—leprosy	0.000747	0.00652	CbGpPWpGaD
Gefitinib—Erythema multiforme—Thalidomide—leprosy	0.000729	0.00727	CcSEcCtD
Gefitinib—Eye disorder—Thalidomide—leprosy	0.00072	0.00719	CcSEcCtD
Gefitinib—Cardiac disorder—Thalidomide—leprosy	0.000715	0.00714	CcSEcCtD
Gefitinib—IRAK4—Toll Like Receptor 4 (TLR4) Cascade—RIPK2—leprosy	0.000713	0.00623	CbGpPWpGaD
Gefitinib—IRAK4—Toll Like Receptor 4 (TLR4) Cascade—TLR2—leprosy	0.000713	0.00623	CbGpPWpGaD
Gefitinib—IRAK4—Signaling by Interleukins—NOD2—leprosy	0.000713	0.00622	CbGpPWpGaD
Gefitinib—Angiopathy—Thalidomide—leprosy	0.000699	0.00698	CcSEcCtD
Gefitinib—IRAK1—TRAF6 Mediated Induction of proinflammatory cytokines—RIPK2—leprosy	0.000699	0.0061	CbGpPWpGaD
Gefitinib—Mediastinal disorder—Thalidomide—leprosy	0.000695	0.00693	CcSEcCtD
Gefitinib—Arrhythmia—Thalidomide—leprosy	0.000689	0.00687	CcSEcCtD
Gefitinib—IRAK4—Activated TLR4 signalling—NOD2—leprosy	0.000688	0.006	CbGpPWpGaD
Gefitinib—Alopecia—Thalidomide—leprosy	0.000681	0.00679	CcSEcCtD
Gefitinib—Vomiting—Dapsone—leprosy	0.00068	0.00678	CcSEcCtD
Gefitinib—Malnutrition—Thalidomide—leprosy	0.000671	0.00669	CcSEcCtD
Gefitinib—IRAK1—Regulation of toll-like receptor signaling pathway—CYLD—leprosy	0.000662	0.00578	CbGpPWpGaD
Gefitinib—IRAK1—p75 NTR receptor-mediated signalling—RIPK2—leprosy	0.000651	0.00568	CbGpPWpGaD
Gefitinib—IRAK4—Toll Like Receptor 4 (TLR4) Cascade—NOD2—leprosy	0.000647	0.00564	CbGpPWpGaD
Gefitinib—IRAK4—Regulation of toll-like receptor signaling pathway—TLR2—leprosy	0.000643	0.00561	CbGpPWpGaD
Gefitinib—Nausea—Dapsone—leprosy	0.000635	0.00634	CcSEcCtD
Gefitinib—IRAK4—Toll-Like Receptors Cascades—RIPK2—leprosy	0.000635	0.00555	CbGpPWpGaD
Gefitinib—IRAK4—Toll-Like Receptors Cascades—TLR2—leprosy	0.000635	0.00555	CbGpPWpGaD
Gefitinib—IRAK1—TRAF6 Mediated Induction of proinflammatory cytokines—NOD2—leprosy	0.000634	0.00553	CbGpPWpGaD
Gefitinib—IRAK1—MyD88 cascade initiated on plasma membrane—RIPK2—leprosy	0.000632	0.00552	CbGpPWpGaD
Gefitinib—ABCB1—blood vessel—leprosy	0.000629	0.00986	CbGeAlD
Gefitinib—IRAK1—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—RIPK2—leprosy	0.000626	0.00547	CbGpPWpGaD
Gefitinib—Anaemia—Thalidomide—leprosy	0.00062	0.00619	CcSEcCtD
Gefitinib—IRAK1—MyD88 dependent cascade initiated on endosome—RIPK2—leprosy	0.000615	0.00537	CbGpPWpGaD
Gefitinib—Angioedema—Thalidomide—leprosy	0.000613	0.00612	CcSEcCtD
Gefitinib—ORM1—nervous system—leprosy	0.00061	0.00956	CbGeAlD
Gefitinib—Malaise—Thalidomide—leprosy	0.000605	0.00604	CcSEcCtD
Gefitinib—IRAK1—Toll Like Receptor 9 (TLR9) Cascade—RIPK2—leprosy	0.000593	0.00518	CbGpPWpGaD
Gefitinib—Cough—Thalidomide—leprosy	0.000586	0.00584	CcSEcCtD
Gefitinib—IRAK1—MyD88:Mal cascade initiated on plasma membrane—RIPK2—leprosy	0.000583	0.00509	CbGpPWpGaD
Gefitinib—IRAK1—MyD88:Mal cascade initiated on plasma membrane—TLR2—leprosy	0.000583	0.00509	CbGpPWpGaD
Gefitinib—IRAK4—Toll-Like Receptors Cascades—NOD2—leprosy	0.000576	0.00503	CbGpPWpGaD
Gefitinib—IRAK1—MyD88 cascade initiated on plasma membrane—NOD2—leprosy	0.000573	0.005	CbGpPWpGaD
Gefitinib—IRAK1—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NOD2—leprosy	0.000568	0.00496	CbGpPWpGaD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	0.000567	0.00566	CcSEcCtD
Gefitinib—CYP1A1—skin of body—leprosy	0.000561	0.00879	CbGeAlD
Gefitinib—IRAK1—MyD88-independent cascade—RIPK2—leprosy	0.00056	0.00488	CbGpPWpGaD
Gefitinib—Dry mouth—Thalidomide—leprosy	0.000559	0.00557	CcSEcCtD
Gefitinib—IRAK1—MyD88 dependent cascade initiated on endosome—NOD2—leprosy	0.000557	0.00487	CbGpPWpGaD
Gefitinib—IRAK1—Toll-like Receptor Signaling Pathway—TLR2—leprosy	0.000546	0.00477	CbGpPWpGaD
Gefitinib—ALB—testis—leprosy	0.000545	0.00854	CbGeAlD
Gefitinib—Infection—Thalidomide—leprosy	0.000544	0.00543	CcSEcCtD
Gefitinib—Shock—Thalidomide—leprosy	0.000539	0.00537	CcSEcCtD
Gefitinib—IRAK1—Toll Like Receptor 9 (TLR9) Cascade—NOD2—leprosy	0.000538	0.0047	CbGpPWpGaD
Gefitinib—Nervous system disorder—Thalidomide—leprosy	0.000537	0.00536	CcSEcCtD
Gefitinib—Thrombocytopenia—Thalidomide—leprosy	0.000536	0.00535	CcSEcCtD
Gefitinib—Skin disorder—Thalidomide—leprosy	0.000532	0.00531	CcSEcCtD
Gefitinib—IRAK1—MyD88:Mal cascade initiated on plasma membrane—NOD2—leprosy	0.000529	0.00462	CbGpPWpGaD
Gefitinib—IRAK1—EBV LMP1 signaling—TNF—leprosy	0.000525	0.00458	CbGpPWpGaD
Gefitinib—Anorexia—Thalidomide—leprosy	0.000522	0.00521	CcSEcCtD
Gefitinib—IRAK1—Signaling by Interleukins—RIPK2—leprosy	0.000522	0.00456	CbGpPWpGaD
Gefitinib—Hypotension—Thalidomide—leprosy	0.000512	0.0051	CcSEcCtD
Gefitinib—IRAK1—MyD88-independent cascade—NOD2—leprosy	0.000507	0.00443	CbGpPWpGaD
Gefitinib—IRAK1—Activated TLR4 signalling—TLR2—leprosy	0.000503	0.00439	CbGpPWpGaD
Gefitinib—IRAK1—Activated TLR4 signalling—RIPK2—leprosy	0.000503	0.00439	CbGpPWpGaD
Gefitinib—Dyspnoea—Thalidomide—leprosy	0.000488	0.00487	CcSEcCtD
Gefitinib—Decreased appetite—Thalidomide—leprosy	0.000476	0.00475	CcSEcCtD
Gefitinib—IRAK1—Toll Like Receptor 4 (TLR4) Cascade—TLR2—leprosy	0.000474	0.00413	CbGpPWpGaD
Gefitinib—IRAK1—Toll Like Receptor 4 (TLR4) Cascade—RIPK2—leprosy	0.000474	0.00413	CbGpPWpGaD
Gefitinib—IRAK1—Signaling by Interleukins—NOD2—leprosy	0.000473	0.00413	CbGpPWpGaD
Gefitinib—Gastrointestinal disorder—Thalidomide—leprosy	0.000473	0.00472	CcSEcCtD
Gefitinib—Fatigue—Thalidomide—leprosy	0.000472	0.00471	CcSEcCtD
Gefitinib—Pain—Thalidomide—leprosy	0.000468	0.00467	CcSEcCtD
Gefitinib—Constipation—Thalidomide—leprosy	0.000468	0.00467	CcSEcCtD
Gefitinib—IRAK1—Activated TLR4 signalling—NOD2—leprosy	0.000456	0.00398	CbGpPWpGaD
Gefitinib—Gastrointestinal pain—Thalidomide—leprosy	0.000448	0.00447	CcSEcCtD
Gefitinib—Urticaria—Thalidomide—leprosy	0.000435	0.00434	CcSEcCtD
Gefitinib—Body temperature increased—Thalidomide—leprosy	0.000433	0.00432	CcSEcCtD
Gefitinib—Abdominal pain—Thalidomide—leprosy	0.000433	0.00432	CcSEcCtD
Gefitinib—IRAK1—Toll Like Receptor 4 (TLR4) Cascade—NOD2—leprosy	0.000429	0.00375	CbGpPWpGaD
Gefitinib—IRAK1—Regulation of toll-like receptor signaling pathway—TLR2—leprosy	0.000427	0.00372	CbGpPWpGaD
Gefitinib—IRAK1—Toll-Like Receptors Cascades—RIPK2—leprosy	0.000422	0.00368	CbGpPWpGaD
Gefitinib—IRAK1—Toll-Like Receptors Cascades—TLR2—leprosy	0.000422	0.00368	CbGpPWpGaD
Gefitinib—Hypersensitivity—Thalidomide—leprosy	0.000403	0.00402	CcSEcCtD
Gefitinib—Asthenia—Thalidomide—leprosy	0.000393	0.00392	CcSEcCtD
Gefitinib—Pruritus—Thalidomide—leprosy	0.000387	0.00386	CcSEcCtD
Gefitinib—IRAK1—Toll-Like Receptors Cascades—NOD2—leprosy	0.000382	0.00334	CbGpPWpGaD
Gefitinib—Diarrhoea—Thalidomide—leprosy	0.000375	0.00374	CcSEcCtD
Gefitinib—ABCG2—testis—leprosy	0.000372	0.00584	CbGeAlD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—RIPK2—leprosy	0.000367	0.0032	CbGpPWpGaD
Gefitinib—Vomiting—Thalidomide—leprosy	0.000348	0.00347	CcSEcCtD
Gefitinib—CYP1A1—nervous system—leprosy	0.000347	0.00544	CbGeAlD
Gefitinib—Rash—Thalidomide—leprosy	0.000345	0.00344	CcSEcCtD
Gefitinib—Dermatitis—Thalidomide—leprosy	0.000345	0.00344	CcSEcCtD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—NOD2—leprosy	0.000333	0.0029	CbGpPWpGaD
Gefitinib—MAP2K5—Cardiac Hypertrophic Response—TNF—leprosy	0.000326	0.00284	CbGpPWpGaD
Gefitinib—Nausea—Thalidomide—leprosy	0.000325	0.00324	CcSEcCtD
Gefitinib—ERBB3—Apoptosis-related network due to altered Notch3 in ovarian cancer—TNF—leprosy	0.000323	0.00282	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—CYLD—leprosy	0.000319	0.00279	CbGpPWpGaD
Gefitinib—IRAK4—Signaling by Interleukins—IL2—leprosy	0.000315	0.00275	CbGpPWpGaD
Gefitinib—EGFR—Aryl Hydrocarbon Receptor Pathway—IFNG—leprosy	0.000311	0.00272	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling by NGF—RIPK2—leprosy	0.000298	0.00261	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by NGF—RIPK2—leprosy	0.000288	0.00251	CbGpPWpGaD
Gefitinib—EGFR—Aryl Hydrocarbon Receptor Pathway—IL2—leprosy	0.000277	0.00242	CbGpPWpGaD
Gefitinib—EGFR—SHP2 signaling—IFNG—leprosy	0.000259	0.00226	CbGpPWpGaD
Gefitinib—CYP2D6—testis—leprosy	0.000255	0.004	CbGeAlD
Gefitinib—ERBB3—Innate Immune System—CYLD—leprosy	0.000255	0.00222	CbGpPWpGaD
Gefitinib—CYP3A4—nervous system—leprosy	0.000255	0.00399	CbGeAlD
Gefitinib—CYP2D6—nervous system—leprosy	0.000251	0.00393	CbGeAlD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—RIPK2—leprosy	0.000244	0.00213	CbGpPWpGaD
Gefitinib—IRAK4—Toll-like Receptor Signaling Pathway—TNF—leprosy	0.00024	0.0021	CbGpPWpGaD
Gefitinib—IRAK1—Signaling by NGF—RIPK2—leprosy	0.00024	0.00209	CbGpPWpGaD
Gefitinib—MAP2K5—MicroRNAs in cardiomyocyte hypertrophy—TNF—leprosy	0.000232	0.00202	CbGpPWpGaD
Gefitinib—EGFR—SHP2 signaling—IL2—leprosy	0.00023	0.00201	CbGpPWpGaD
Gefitinib—EGFR—Regulation of Telomerase—IFNG—leprosy	0.000228	0.00199	CbGpPWpGaD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—HLA-DRB1—leprosy	0.000226	0.00198	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—NOD2—leprosy	0.000221	0.00193	CbGpPWpGaD
Gefitinib—MKNK1—MAPK Signaling Pathway—TNF—leprosy	0.000217	0.00189	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—PARK2—leprosy	0.000216	0.00189	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—CYLD—leprosy	0.000212	0.00185	CbGpPWpGaD
Gefitinib—IRAK1—Signaling by Interleukins—IL2—leprosy	0.000209	0.00182	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—TLR2—leprosy	0.000206	0.0018	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—RIPK2—leprosy	0.000206	0.0018	CbGpPWpGaD
Gefitinib—MKNK1—Disease—SLC11A1—leprosy	0.000204	0.00178	CbGpPWpGaD
Gefitinib—EGFR—Regulation of Telomerase—IL2—leprosy	0.000202	0.00177	CbGpPWpGaD
Gefitinib—EGFR—Aryl Hydrocarbon Receptor—TNF—leprosy	0.000202	0.00176	CbGpPWpGaD
Gefitinib—EGFR—Aryl Hydrocarbon Receptor Pathway—TNF—leprosy	0.000202	0.00176	CbGpPWpGaD
Gefitinib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—leprosy	0.000197	0.00172	CbGpPWpGaD
Gefitinib—IRAK4—Regulation of toll-like receptor signaling pathway—TNF—leprosy	0.000187	0.00164	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—NOD2—leprosy	0.000187	0.00163	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CYLD—leprosy	0.000186	0.00162	CbGpPWpGaD
Gefitinib—ABCB1—testis—leprosy	0.000184	0.00288	CbGeAlD
Gefitinib—ABCB1—nervous system—leprosy	0.00018	0.00283	CbGeAlD
Gefitinib—CHEK2—Integrated Pancreatic Cancer Pathway—TNF—leprosy	0.000177	0.00155	CbGpPWpGaD
Gefitinib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—leprosy	0.000175	0.00153	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—IL10—leprosy	0.000173	0.00151	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—CD40LG—leprosy	0.000173	0.00151	CbGpPWpGaD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—IFNG—leprosy	0.000165	0.00144	CbGpPWpGaD
Gefitinib—ALB—Vitamin B12 Metabolism—IFNG—leprosy	0.000165	0.00144	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—PARK2—leprosy	0.000164	0.00144	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—RIPK2—leprosy	0.000164	0.00143	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—TLR2—leprosy	0.000164	0.00143	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—RIPK2—leprosy	0.00016	0.0014	CbGpPWpGaD
Gefitinib—IRAK1—Toll-like Receptor Signaling Pathway—TNF—leprosy	0.000159	0.00139	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—SLC11A1—leprosy	0.000159	0.00139	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—RIPK2—leprosy	0.000158	0.00138	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—HLA-DRB1—leprosy	0.00015	0.00131	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—NOD2—leprosy	0.000149	0.0013	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CYLD—leprosy	0.000148	0.00129	CbGpPWpGaD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—IL2—leprosy	0.000147	0.00128	CbGpPWpGaD
Gefitinib—EGFR—Spinal Cord Injury—IFNG—leprosy	0.000147	0.00128	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—CYLD—leprosy	0.000142	0.00124	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—HLA-DRB1—leprosy	0.00014	0.00122	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—RIPK2—leprosy	0.000137	0.00119	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—TLR2—leprosy	0.000137	0.00119	CbGpPWpGaD
Gefitinib—ALB—SLC-mediated transmembrane transport—SLC11A1—leprosy	0.000137	0.00119	CbGpPWpGaD
Gefitinib—ALB—Folate Metabolism—IFNG—leprosy	0.000134	0.00117	CbGpPWpGaD
Gefitinib—MAP2K5—MAPK Signaling Pathway—TNF—leprosy	0.000133	0.00116	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—PARK2—leprosy	0.000131	0.00114	CbGpPWpGaD
Gefitinib—EGFR—Spinal Cord Injury—IL2—leprosy	0.00013	0.00114	CbGpPWpGaD
Gefitinib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—leprosy	0.000127	0.00111	CbGpPWpGaD
Gefitinib—CYP1A1—Aryl Hydrocarbon Receptor—TNF—leprosy	0.000127	0.00111	CbGpPWpGaD
Gefitinib—IRAK1—Regulation of toll-like receptor signaling pathway—TNF—leprosy	0.000124	0.00109	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—NOD2—leprosy	0.000124	0.00108	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CYLD—leprosy	0.000123	0.00108	CbGpPWpGaD
Gefitinib—ERBB3—Disease—SLC11A1—leprosy	0.000121	0.00106	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—CD40LG—leprosy	0.000121	0.00105	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—PARK2—leprosy	0.00012	0.00105	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—RIPK2—leprosy	0.00012	0.00105	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—TLR2—leprosy	0.00012	0.00105	CbGpPWpGaD
Gefitinib—ALB—Folate Metabolism—IL2—leprosy	0.000119	0.00104	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—CD8A—leprosy	0.000119	0.00104	CbGpPWpGaD
Gefitinib—ABCG2—Transmembrane transport of small molecules—SLC11A1—leprosy	0.000112	0.000982	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—IFNG—leprosy	0.00011	0.000958	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—PARK2—leprosy	0.000109	0.000953	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—NOD2—leprosy	0.000109	0.000949	CbGpPWpGaD
Gefitinib—ALB—Vitamin B12 Metabolism—TNF—leprosy	0.000107	0.000933	CbGpPWpGaD
Gefitinib—ALB—Selenium Micronutrient Network—IFNG—leprosy	0.000107	0.000932	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—RIPK2—leprosy	0.000104	0.00091	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—IFNG—leprosy	0.000102	0.00089	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—IL2—leprosy	9.76e-05	0.000852	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—HLA-DRB1—leprosy	9.72e-05	0.000849	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—RIPK2—leprosy	9.56e-05	0.000834	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—TLR2—leprosy	9.56e-05	0.000834	CbGpPWpGaD
Gefitinib—EGFR—Spinal Cord Injury—TNF—leprosy	9.49e-05	0.000828	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CD40LG—leprosy	9.19e-05	0.000802	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—RIPK2—leprosy	9.13e-05	0.000797	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—TLR2—leprosy	9.13e-05	0.000797	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CD8A—leprosy	9.08e-05	0.000793	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—IL2—leprosy	9.06e-05	0.000791	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—CD4—leprosy	8.96e-05	0.000782	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—RIPK2—leprosy	8.77e-05	0.000766	CbGpPWpGaD
Gefitinib—ALB—Folate Metabolism—TNF—leprosy	8.7e-05	0.000759	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—NOD2—leprosy	8.66e-05	0.000756	CbGpPWpGaD
Gefitinib—EPHA6—Developmental Biology—TNF—leprosy	8.43e-05	0.000736	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—NOD2—leprosy	8.28e-05	0.000723	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CYLD—leprosy	8.26e-05	0.000721	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—RIPK2—leprosy	8.11e-05	0.000708	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—RIPK2—leprosy	7.96e-05	0.000694	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—TLR2—leprosy	7.96e-05	0.000694	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—HLA-DRB1—leprosy	7.4e-05	0.000646	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CD40LG—leprosy	7.32e-05	0.000639	CbGpPWpGaD
Gefitinib—EGFR—Immune System—PARK2—leprosy	7.3e-05	0.000637	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CD8A—leprosy	7.24e-05	0.000632	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—NOD2—leprosy	7.21e-05	0.00063	CbGpPWpGaD
Gefitinib—EGFR—MAPK Signaling Pathway—TNF—leprosy	7.15e-05	0.000624	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—CD4—leprosy	7.14e-05	0.000623	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—SDHD—leprosy	7.01e-05	0.000612	CbGpPWpGaD
Gefitinib—ALB—Transmembrane transport of small molecules—SLC11A1—leprosy	6.94e-05	0.000606	CbGpPWpGaD
Gefitinib—ALB—Selenium Micronutrient Network—TNF—leprosy	6.91e-05	0.000603	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—CD4—leprosy	6.86e-05	0.000599	CbGpPWpGaD
Gefitinib—EGFR—Disease—SLC11A1—leprosy	6.74e-05	0.000588	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CD40LG—leprosy	6.72e-05	0.000587	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CD8A—leprosy	6.65e-05	0.00058	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—TNF—leprosy	6.6e-05	0.000576	CbGpPWpGaD
Gefitinib—MKNK1—Disease—CD4—leprosy	6.48e-05	0.000566	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—TNF—leprosy	6.45e-05	0.000563	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—RIPK2—leprosy	6.41e-05	0.00056	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—RIPK2—leprosy	6.18e-05	0.000539	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CD40LG—leprosy	6.1e-05	0.000532	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—SLC11A1—leprosy	6.08e-05	0.000531	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CD8A—leprosy	6.03e-05	0.000526	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—CD4—leprosy	5.95e-05	0.000519	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—HLA-DRB1—leprosy	5.9e-05	0.000515	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HLA-DRB1—leprosy	5.41e-05	0.000472	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—IFNG—leprosy	5.4e-05	0.000472	CbGpPWpGaD
Gefitinib—EGFR—Immune System—RIPK2—leprosy	5.32e-05	0.000464	CbGpPWpGaD
Gefitinib—EGFR—Immune System—TLR2—leprosy	5.32e-05	0.000464	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CD4—leprosy	5.22e-05	0.000455	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—RIPK2—leprosy	5.14e-05	0.000449	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—CD4—leprosy	5.04e-05	0.00044	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—SDHD—leprosy	5.02e-05	0.000438	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HLA-DRB1—leprosy	4.91e-05	0.000429	CbGpPWpGaD
Gefitinib—EGFR—Immune System—NOD2—leprosy	4.82e-05	0.000421	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—IL2—leprosy	4.8e-05	0.000419	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—SDHD—leprosy	4.74e-05	0.000414	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—IL2—leprosy	4.54e-05	0.000396	CbGpPWpGaD
Gefitinib—ALB—Metabolism—SDHD—leprosy	4.33e-05	0.000378	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IFNG—leprosy	4.31e-05	0.000376	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—IL2—leprosy	4.18e-05	0.000365	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CD4—leprosy	4.16e-05	0.000363	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CD40LG—leprosy	4.08e-05	0.000356	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CD8A—leprosy	4.03e-05	0.000352	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—CD4—leprosy	3.98e-05	0.000347	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—SDHD—leprosy	3.88e-05	0.000339	CbGpPWpGaD
Gefitinib—ERBB3—Disease—CD4—leprosy	3.84e-05	0.000335	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IL2—leprosy	3.83e-05	0.000334	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CD4—leprosy	3.82e-05	0.000333	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—SDHD—leprosy	3.79e-05	0.000331	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IFNG—leprosy	3.59e-05	0.000313	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—SDHD—leprosy	3.57e-05	0.000312	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—SDHD—leprosy	3.54e-05	0.000309	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CD4—leprosy	3.46e-05	0.000302	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—RIPK2—leprosy	3.44e-05	0.0003	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HLA-DRB1—leprosy	3.28e-05	0.000287	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—leprosy	3.26e-05	0.000284	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—IL2—leprosy	3.25e-05	0.000283	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL2—leprosy	3.19e-05	0.000278	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—TNF—leprosy	3.02e-05	0.000263	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IL2—leprosy	2.57e-05	0.000224	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IL2—leprosy	2.47e-05	0.000216	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IFNG—leprosy	2.4e-05	0.000209	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—IL2—leprosy	2.34e-05	0.000204	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SDHD—leprosy	2.33e-05	0.000204	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—IL2—leprosy	2.33e-05	0.000204	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CD4—leprosy	2.32e-05	0.000202	CbGpPWpGaD
Gefitinib—EGFR—Disease—CD4—leprosy	2.14e-05	0.000187	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL2—leprosy	2.13e-05	0.000186	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL2—leprosy	2.06e-05	0.00018	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL2—leprosy	1.38e-05	0.00012	CbGpPWpGaD
